2. Ringheim GE, Wampole M, Oberoi K. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures. Front Immunol. 2021 Nov 3;12:662223. doi: ...
[2]Le H Hua, Efficacy and Safety of Fenebrutinib, a Noncovalent, Reversible BTK Inhibitor, in MS: Primary Results of a Phase II Trial. 2023EAN. [3]Garg N, Padron EJ, Rammohan KW, Goodman CF.J Clin Med. 2022 Oct 18;11(20):6139. [4]Satterthwaite AB, et al. Semin Immunol 1998;...
4. Woyach J A, Flinn I W, Awan F T, et al. Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-Cell malignancies: Updated analysis of the open-label phase 1/2 ...
1. ClinicalTrials.gov. A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL. NCT identifier: NCT02970318. https://clinicaltrials.gov/ct2/show/NCT02970318. Accessed May 2022. 2. Zhu J, et al. Pharmacokinetics, Safety, and...
13. Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9(21) (来源:阿斯利康网站)
China NMPA approves clinical trial of InnoCare’s BTK inhibitor, orelabrutinib in combo with R-CHOP for previously untreated patients with mantle cell lymphoma
1.Smith PF, Redfern A, Shu J, et al. Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety,CNS Exposure and Therapeutic Levels of BTK Occupancy[J]. ACTRIMS, Feb 28, 2019, P072. 2.Reich DS, ...
1.Smith PF, Redfern A, Shu J, et al. Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety,CNS Exposure and Therapeutic Levels of BTK Occupancy[J]. ACTRIMS, Feb 28, 2019, P072. 2.Reich DS, Arnold DL, Vermersch P, et al. Safety and efficacy ...
SAT0232 A Phase 1 Clinical Trial of PRN1008, an Oral, Reversible, Covalent BTK Inhibitor Demonstrates Clinical Safety and Therapeutic Levels of BTK Occupancy Without Sustained Systemic ExposureBackground Bruton's tyrosine kinase (BTK) plays a role in signaling pathways of the B cell receptor, Fc...
Findings from the phase 3 SHINE (NCT01776840), ACE-LY-308 (NCT02972840), and SYMPATICO (NCT03112174) clinical trials incorporating BTK inhibitors in combination with BR or using BTK inhibitor plus venetoclax (Venclexta) as frontline therapy could potentially change the treatment paradigm for ...